Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics Inc (RNAZ) is a clinical-stage biopharmaceutical company pioneering RNA-based therapies for metastatic cancers through its proprietary TTX nanoparticle delivery platform. This news hub provides investors and researchers with essential updates on the company’s progress in developing targeted treatments, including its lead candidate TTX-MC138 designed to inhibit metastasis-driving microRNA-10b.
Our curated collection offers immediate access to official press releases, clinical trial milestones, and strategic partnership announcements. Users will find updates spanning multiple critical areas: TTX platform advancements, regulatory submissions, financial disclosures, and peer-reviewed research collaborations in oncology.
Key content includes developments around the company’s nanoparticle delivery system, trial results for metastatic cancer therapies, and analyses of RNAZ’s position within the competitive oncology therapeutics market. All materials are sourced directly from company filings and verified industry publications to ensure reliability.
Bookmark this page for streamlined tracking of TransCode’s innovations in RNA oncology. Check regularly for new insights into how the company’s cutting-edge approach to metastatic disease treatment continues to evolve through clinical validation and strategic execution.
TransCode Therapeutics (RNAZ) announced the adjournment of its Special Meeting scheduled for April 21, 2025, due to insufficient quorum, with only 12.73% of eligible shares represented. The meeting will reconvene as a virtual Adjourned Special Meeting on May 2, 2025.
The meeting aims to vote on two key proposals: Proposal One seeks approval for a reverse stock split ranging from 1:10 to 1:40 ratio, while Proposal Two addresses the potential need for further meeting adjournments. Stockholders of record as of April 2, 2025, can vote through multiple methods including mail, internet, telephone, or during the virtual meeting at www.virtualshareholdermeeting.com/RNAZ2025SM2.
TransCode Therapeutics (NASDAQ: RNAZ) has announced significant progress in its Phase 1 clinical trial of TTX-MC138, their lead therapeutic candidate designed to inhibit microRNA-10b in metastatic cancer. The first patient in Cohort 4 has received initial dosing, with two additional patients scheduled for treatment.
Key highlights include:
- Ten patients treated across four cohorts at escalating dose levels
- No significant safety or dose-limiting toxicities reported
- Seven patients remain on study for continued treatment
- Cohort 4 dosing is approximately 50% higher than Cohort 3
- Ongoing data analysis from Cohorts 1-3 shows pharmacokinetic and pharmacodynamic profiles consistent with preclinical results and Phase 0 trial
The Safety Review Committee has approved additional patient enrollment in Cohort 3 to further establish the safety profile of TTX-MC138.
TransCode Therapeutics (RNAZ) has completed a registered direct offering, raising $10 million in gross proceeds through the sale of 10,250,000 shares of common stock and accompanying warrants. The offering was priced at $0.98 per share at-the-market under Nasdaq rules, with each share accompanied by warrants to purchase additional shares.
The RNA oncology company plans to utilize the proceeds primarily for product development activities, including clinical trials of their lead therapeutic candidate TTX-MC138, IND-enabling studies, working capital, and general corporate purposes. ThinkEquity served as the sole placement agent for this offering, which was conducted under an effective shelf registration statement filed with the SEC.
TransCode Therapeutics (NASDAQ: RNAZ) has announced a registered direct offering of 10,250,000 shares of common stock and warrants at $0.98 per share. The offering includes warrants to purchase up to 10,250,000 additional shares at an exercise price of $0.86, exercisable for five years upon issuance.
The offering, expected to close on March 25, 2025, aims to raise approximately $10 million in gross proceeds. The funds will support product development activities, including clinical trials for TTX-MC138 (their lead therapeutic candidate), IND-enabling studies, working capital, and general corporate purposes. ThinkEquity serves as the exclusive placement agent for this at-the-market offering under Nasdaq rules.
TransCode Therapeutics (NASDAQ: RNAZ) has received approval from the Safety Review Committee (SRC) to proceed with Cohort 4 in its Phase I/II clinical trial for TTX-MC138, a first-in-class RNA therapeutic for metastatic cancers. The approval follows favorable safety data from Cohort 3, with no significant safety issues or dose-limiting toxicities reported across all three previous cohorts.
Key highlights:
- 6 out of 9 treated patients remain on study, with one patient receiving 7 doses over approximately 7 months
- Cohort 4 will receive a dose approximately 50% higher than Cohort 3
- SRC approved additional patient enrollment in Cohort 3
- Pharmacokinetic and pharmacodynamic data from Cohorts 1 and 2 align with preclinical and Phase 0 trial results
- Preliminary analysis suggests dose levels of 0.8-1.6 mg/kg could represent an efficacious range
TransCode Therapeutics (RNAZ), the RNA Oncology Company, announced the results of its Special Meeting held on February 25, 2025, following adjournment from February 4, 2025. Shareholders achieved a quorum and approved two key proposals:
- Proposal One: Approved the issuance of Common Stock upon exercise of Series C and D Warrants, including adjustments to warrant exercise prices, an alternative cashless exercise feature for Series D Warrants, and potential future price adjustments (subject to a $2.4882 floor price)
- Proposal Two: Approved the ability to adjourn the Special Meeting if needed for further proxy solicitation regarding the Issuance Proposal
TransCode Therapeutics (NASDAQ: RNAZ) has announced the completion of initial dosing in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, its lead candidate. Three patients were enrolled and dosed in Cohort 3, with the dose being approximately double that of Cohort 2. The Safety Review Committee approved the third cohort after reviewing safety and pharmacokinetic (PK) data from Cohorts 1 and 2.
Notable findings include: no significant safety or dose limiting toxicities reported across all nine trial patients; several patients from Cohorts 1 and 2 continuing treatment in 28-day cycles; and PK/PD analyses showing consistency with preclinical and Phase 0 trial results. Cohort 1 demonstrated 66% inhibition of miR-10b at 24 hours post-infusion, matching Phase 0 observations. TTX-MC138 showed increased activity with dose escalation in Cohort 2, maintaining consistency across subsequent administrations.
TransCode Therapeutics (RNAZ) announced the adjournment of its Special Meeting scheduled for February 4, 2025, due to insufficient quorum. Only 29.94% of eligible voting shares were represented, falling short of the required one-third minimum. The meeting has been rescheduled to February 25, 2025, at 9:30 a.m. Eastern time.
The adjourned meeting will address two key proposals: Proposal One concerns the issuance of Common Stock upon exercise of Series C and D Warrants, including price adjustments and exercise features, subject to a floor price of $2.4882. Proposal Two addresses the potential need for further meeting adjournments if insufficient votes are received for Proposal One.
Stockholders of record as of December 17, 2024, can vote through multiple methods including mail, internet, telephone, or during the virtual meeting. All votes must be received by 11:59 p.m. Eastern time on February 24, 2025.
TransCode Therapeutics (NASDAQ: RNAZ) has announced the dosing of the first patient in Cohort 3 of its Phase 1 clinical trial for TTX-MC138, its lead candidate. The Safety Review Committee (SRC) unanimously approved the third cohort after reviewing favorable safety and pharmacokinetic data from Cohorts 1 and 2.
Key highlights include:
- No significant safety or dose-limiting toxicities reported in previous cohorts
- Cohort 3 dosage is approximately double that of Cohort 2
- Several patients from earlier cohorts continue treatment
- TTX-MC138 showed 66% inhibition of miR-10b at 24 hours post-infusion in Cohort 1
- Increased activity observed with escalated dose in Cohort 2
- PK/PD profile aligns with preclinical and Phase 0 trial results
TransCode Therapeutics (NASDAQ: RNAZ) has announced that it has regained compliance with Nasdaq's listing requirements, including minimum bid price and shareholders' equity rules. The company has also resolved a violation regarding the Shareholder Approval Rule through shareholder ratification of a July 2024 equity transaction.
The company will remain listed on the Nasdaq Capital Market but will be subject to a Discretionary Panel Monitor through December 24, 2025. If TransCode fails to maintain compliance with any listing rule during this period, it will not be granted additional time to regain compliance and may face delisting, though it will have the opportunity to request a new hearing.
Tom Fitzgerald, TransCode's Interim CEO and CFO, expressed optimism about the company's future, highlighting their focus on advancing their lead therapeutic candidate, TTX-MC138, in clinical trials.
